Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Oka

Showing results (61-70 of 966) with videos related to

Pageof 97
Sort By:
Scandinavian Journal of Rheumatology|January 1, 1974
Radiation synovectomy. Results in rheumatoid knee effusions treated with radioactive yttriumM Oka, M Hypén
British Journal of Cancer|July 29, 2004
CIITA methylation and decreased levels of HLA-DR in tumour progressionN Iizuka, M Oka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1996
[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL]Y Masaki, M Oka
Scandinavian Journal of Rheumatology|February 11, 2010
Muramidase (lysozyme) in joint fluid and serum of rheumatic patientsM Oka, O Seppälä
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1994
[Strategy of treatment for pancreatic and biliary cancer with special reference to immunotherapy]M Oka, T Suzuki
Journal of Enzyme Inhibition|August 8, 2002
Aldose reductase inhibitorsM Oka, N Kato
The Journal of Nutrition|April 1, 1985
Urinary lumichrome-level catabolites of riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl chainM Oka, D B McCormick
The Gerontologist|October 1, 1995
An older-worker employment model: Japan's Silver Human Resource CentersS A Bass, M Oka
Prostaglandins and Medicine|March 1, 1980
Spironolactone decreases the formation of prostaglandins and related substances from arachidonic acid in rat vascular rings and human plateletsM Oka, M S Manku
Prostaglandins and Medicine|October 1, 1981
Spironolactone inhibits vascular reactivity by a prostaglandin related mechanism unconnected with aldosteroneM Oka, M S Manku
Pageof 97

Showing results (61-70 of 966) with videos related to

Sort By:
Pageof 97
Scandinavian Journal of Rheumatology|January 1, 1974
Radiation synovectomy. Results in rheumatoid knee effusions treated with radioactive yttriumM Oka, M Hypén
British Journal of Cancer|July 29, 2004
CIITA methylation and decreased levels of HLA-DR in tumour progressionN Iizuka, M Oka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 1, 1996
[Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL]Y Masaki, M Oka
Scandinavian Journal of Rheumatology|February 11, 2010
Muramidase (lysozyme) in joint fluid and serum of rheumatic patientsM Oka, O Seppälä
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1994
[Strategy of treatment for pancreatic and biliary cancer with special reference to immunotherapy]M Oka, T Suzuki
Journal of Enzyme Inhibition|August 8, 2002
Aldose reductase inhibitorsM Oka, N Kato
The Journal of Nutrition|April 1, 1985
Urinary lumichrome-level catabolites of riboflavin are due to microbial and photochemical events and not rat tissue enzymatic cleavage of the ribityl chainM Oka, D B McCormick
The Gerontologist|October 1, 1995
An older-worker employment model: Japan's Silver Human Resource CentersS A Bass, M Oka
Prostaglandins and Medicine|March 1, 1980
Spironolactone decreases the formation of prostaglandins and related substances from arachidonic acid in rat vascular rings and human plateletsM Oka, M S Manku
Prostaglandins and Medicine|October 1, 1981
Spironolactone inhibits vascular reactivity by a prostaglandin related mechanism unconnected with aldosteroneM Oka, M S Manku
Pageof 97